| 卡维地洛治疗肝硬化门静脉高压症的作用机制及应用现状 |
| |
| 引用本文： | 何搏,张春清. 卡维地洛治疗肝硬化门静脉高压症的作用机制及应用现状[J]. 临床肝胆病杂志, 2019, 35(2): 399-401 |
| |
| 作者姓名： | 何搏 张春清 |
| |
| 作者单位： | 山东大学附属省立医院消化内科,济南,250021;山东大学附属省立医院消化内科,济南,250021 |
| |
| 摘 要： | 肝硬化门静脉高压症的形成依赖于肝内血管阻力的增加及血流高动力状态。卡维地洛因其特有的降低肝内血管阻力作用,理论上具有更好的降低门静脉高压的效果。归纳了卡维地洛降低门静脉高压已知及可能的机制,回顾了卡维地洛治疗肝硬化门静脉高压症的最新研究。认为卡维地洛有望成为治疗肝硬化门静脉高压症的核心药物,而他汀类药物可能成为其最佳搭档。
|
| 关 键 词： | 肝硬化 高血压,门静脉 卡维地洛 综述 |
Mechanism and current status of carvedilol in treatment of cirrhotic portal hypertension |
| |
| HE Bo,ZHANG Chunqing. Mechanism and current status of carvedilol in treatment of cirrhotic portal hypertension[J]. Chinese Journal of Clinical Hepatology, 2019, 35(2): 399-401 |
| |
| Authors: | HE Bo ZHANG Chunqing |
| |
| Affiliation: | (Department of Gastroenterology,Shandong Provincial Hospital Affiliated to Shandong University,Jinan 250021,China) |
| |
| Abstract: | The formation of cirrhotic portal hypertension depends on the increase in intrahepatic vascular resistance and the state of hyperdynamic circulation.The specific effect of carvedilol in reducing intrahepatic vascular resistance has a better effect in alleviating portal hypertension in theory.This article summarizes the known and possible mechanisms of carvedilol in reducing portal hypertension and reviews the latest research advances in the role of carvedilol in the treatment of cirrhotic portal hypertension.It is pointed out that carvedilol is expected to become the core drug in the treatment of cirrhotic portal hypertension,and statins may be their best partner. |
| |
| Keywords: | liver cirrhosis hypertension,portal carvedilol review |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
